India's Covid-19 vaccine Covaxin 'safe', triggers immune response in Phase I trials

Top Stories

A medic fills a syringe with COVAXIN, an Indian government-backed experimental COVID-19 vaccine at the Gujarat Medical Education and Research Society in Ahmedabad, India, November 26, 2020.
A medic fills a syringe with COVAXIN, an Indian government-backed experimental COVID-19 vaccine at the Gujarat Medical Education and Research Society in Ahmedabad, India, November 26, 2020.

Mumbai, India - 'No adverse events were reported' in the trial, the developers Bharat Biotech added.

By Reuters

  • Follow us on
  • google-news
  • whatsapp
  • telegram

Published: Wed 16 Dec 2020, 10:15 PM

Last updated: Wed 16 Dec 2020, 10:23 PM

An Indian government-backed Covid-19 vaccine showed it was safe and triggered immune responses during an ongoing early-stage trial, the company involved in the study said in a statement on Wednesday.

Also read: India 'likely to emerge' as country with highest Covid-19 tally


Bharat Biotech, the private company developing Covaxin with the government-run Indian Council of Medical Research (ICMR), said: "Covaxin demonstrated acceptable safety profile and high immune response. . . No serious (grade 3-4) adverse events were reported."

Phase II and Phase III clinical trials are underway.


The company earlier this month sought emergency-use authorisation from the Indian drug regulator for its Covid-19 vaccine to help achieve its plan to launch COVAXIN by the second quarter of 2021.

India has the world's second-highest caseload of coronavirus behind the United States, and it is looking to deploy its vast election machinery to deliver 600 million doses of Covid-19 vaccines to the most vulnerable people in the next six to eight months.


More news from